Gestion péri-opératoire des nouveaux anticoagulants oraux

Legrand, 2011, The use of dabigatran in elderly patients, Arch Intern Med, 171, 1285, 10.1001/archinternmed.2011.314 Lillo-Le Louët, 2012, Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation, Thromb Haemost, 108, 583, 10.1160/TH12-03-0149 Warkentin, 2012, Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding, Blood, 119, 2172, 10.1182/blood-2011-11-393587 Healey, 2012, Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial, Circulation, 126, 343, 10.1161/CIRCULATIONAHA.111.090464 Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638 Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039 EINSTEIN Investigators, 2010, Oral rivaroxaban for symptomatic venous thromboembolism, N Engl J Med, 363, 2499, 10.1056/NEJMoa1007903 EINSTEIN-PE Investigators, 2012, Oral rivaroxaban for the treatment of symptomatic pulmonary embolism, N Eng J Med, 366, 1287, 10.1056/NEJMoa1113572 Sié, 2011, Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on perioperative haemostasis and the French Study Group on thrombosis and haemostasis, Arch Cardiovascular Dis, 104, 669, 10.1016/j.acvd.2011.09.001 Sié, 2012, Chirurgies et actes invasifs chez les patients traités au long cours par un anticoagulant oral anti-IIa ou anti-Xadirect. Actualisation 2012, STV, 24, 269 Godier, 2012, Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model, Anesthesiology, 116, 94, 10.1097/ALN.0b013e318238c036 Eerenberg, 2011, Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects, Circulation, 124, 1573, 10.1161/CIRCULATIONAHA.111.029017 Kaatz, 2012, Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors, Am J Hematol, 87, S141, 10.1002/ajh.23202 Marlu, 2012, Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers, Thromb Haemost, 108, 217, 10.1160/TH12-03-0179 Lambourne, 2012, Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate, J Thromb Haemost, 10, 1830, 10.1111/j.1538-7836.2012.04863.x Pragst, 2012, Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model, J Thromb Haemost, 10, 1841, 10.1111/j.1538-7836.2012.04859.x Martin, 2013, Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis, Int J Cardiol, 168, 4228, 10.1016/j.ijcard.2013.07.152 Schulman, 2014, Activated prothrombin complex concentrate for dabigatran-associated bleeding, Br J Haematol, 164, 308, 10.1111/bjh.12620 Schiele, 2013, A specific antidote for dabigatran: functional and structural characterization, Blood, 121, 3554, 10.1182/blood-2012-11-468207 Lu, 2013, A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa, Nat Med, 19, 446, 10.1038/nm.3102 Chen, 2013, Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose, Am J Kidney Dis, 62, 591, 10.1053/j.ajkd.2013.02.361 Khadzhynov, 2013, Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease, Thromb Haemost, 109, 596, 10.1160/TH12-08-0573 van Ryn, 2010, Dabigatran etexilate–a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity, Thromb Haemost, 103, 1116, 10.1160/TH09-11-0758 Samama, 2010, Assessment of laboratory assays to measure rivaroxaban–an oral, direct factor Xa inhibitor, Thromb Haemost, 103, 815, 10.1160/TH09-03-0176 Weitz, 2008, New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition), Chest, 133, 234S, 10.1378/chest.08-0673 Haute Autorité de santé, 2014 Pernod, 2013, Prise en charge des complications hémorragiques graves et de la chirurgie en urgence chez les patients recevant un anticoagulant oral anti-IIa ou anti-Xa direct. Propositions du Groupe d’intérêt en Hémostase Périopératoire (GIHP) - mars 2013, Ann Fr Anesth Reanim, 32, 691, 10.1016/j.annfar.2013.04.016